Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 53
Sustained leadership position in the European modern and
new-generation insulin market
European insulin market by segment
Device penetration
CAGR volume1: 2.1%
CAGR value1:
2.4%
European modern insulin and new-generation
insulin volume market shares
Sanofi
Novo Nordisk
Eli Lilly
-
tMU
180
160
140
120
100
80
60
40
20
0
Nov
2012
MI and NGI penetration
Penetration
100%
60%
50%
80%
Fast-acting
40%
60%
30%
Premix
40%
20%
Long-acting 20%
10%
0%
0%
Nov
2017
Nov
2012
44%
36%
19%
Nov
2017
1 CAGR for 5-year period
2 MI: Modern insulin; NGI: New-generation insulin
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume and value (DKK) figures
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures, numbers do not add up to 100%
due to smaller insulin manufacturers
changing
diabetes®
novo nordiskView entire presentation